S&P 500 7,723.39 ▲ 46.62 (+0.61%) DOW 52,389.06 ▲ 27.48 (+0.05%) NASDAQ 26,480.43 ▲ 311.05 (+1.19%) US Markets Closed â€ĸ 05:49 PM ET

NEUP

Neuphoria Therapeutics Inc.

Price Chart
Latest Quote

$3.38

-0.04 (-1.17%)
Current Price
Previous Close $3.42
Open $3.39
Day High $3.46
Day Low $3.35
Volume 26,699
Fetched: 2026-10-27T06:40:46
Stock Information
Shares Outstanding 5.41M
Total Debt $34K
Cash Equivalents $19.87M
Revenue $1.17M
Net Income $-13.45M
Sector Healthcare
Industry Biotechnology
Market Cap $18.34M
EPS (TTM) $-3.06
Exchange NGM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$-1.54M
Sales$1.17M
Income$-13.45M
Book/sh$4.55
Cash/sh$3.67
Employees1
Financial Ratios
Quick Ratio27.33
Current Ratio27.85
Debt/Eq0.14
Returns & Margins
ROA-19.66%
ROE-61.70%
Gross Margin100.00%
Operating Margin-15.66%
Ownership
Insider Ownership5.02%
Institutional Ownership42.85%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-1.38
P/S15.62
P/B0.75
Analyst Data
Recommendationnone
Technical Indicators
SMA20$3.40
SMA50$3.62
SMA200$4.18
RSI47.89
ATR0.1246
Shares Float5.37M
Short Float0.45%
Short Ratio1.11
Rel Volume0.16
Performance History
Week+0.00%
Month-7.12%
Quarter-10.79%
6 Months-33.79%
YTD-11.26%
Year-45.67%
3 Years-92.59%
10 Years-98.08%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $3.39 3,638
2026-10-26 $3.38 26,700
2026-10-23 $3.44 73,000
2026-10-22 $3.48 4,800
2026-10-21 $3.48 8,800
2026-10-20 $3.39 20,800
2026-10-19 $3.31 39,500
2026-10-16 $3.30 76,000
2026-10-15 $3.31 18,700
2026-10-14 $3.24 44,100
2026-10-13 $3.39 26,600
2026-10-12 $3.32 10,000
2026-10-09 $3.36 2,500
2026-10-08 $3.35 16,500
2026-10-07 $3.42 4,500
2026-10-06 $3.45 16,500
2026-10-05 $3.45 15,500
2026-10-02 $3.47 12,600
2026-10-01 $3.51 14,300
2026-09-30 $3.56 10,400
2026-09-29 $3.57 15,000
2026-09-28 $3.65 2,900
About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

📰 Latest News
No news articles available at the moment. Check back later for updates on NEUP.
Period:
Loading...
Income Statement (Annual)
Metric 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Revenue
Total Revenue $1,174,165 - $0 $0
Operating Revenue $1,174,165 - $0 $0
Expenses
Total Expenses $10,183,741 - $17,797,161 $21,560,234
Other Income Expense $-5,247,099 - $1,997,578 $-283,775
Net Non Operating Interest Income Expense $665,571 - $220,097 $323,158
Operating Expense $10,183,741 - $17,797,161 $21,560,234
Other Operating Expenses $-800,904 - $-95,215 $-422,742
General And Administrative Expense $7,439,224 - $8,474,591 $8,911,271
Interest Expense - - - $14,085
Rent Expense Supplemental - - - $145,853
Total Other Finance Cost - - - $5,264
Interest Expense Non Operating - - - $14,085
Other Non Operating Income Expenses - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-13,451,931 - $-15,492,166 $-21,381,677
Net Interest Income $665,571 - $220,097 $323,158
Interest Income $665,571 - $220,097 $323,158
Normalized Income $-8,257,303 $-239,149 $-17,477,759 $-21,099,605
Net Income From Continuing And Discontinued Operation $-13,451,931 - $-15,492,166 $-21,381,677
Total Operating Income As Reported $-16,451,066 - $-17,892,376 $-21,982,976
Net Income Common Stockholders $-13,451,931 - $-15,492,166 $-21,381,677
Net Income $-13,451,931 - $-15,492,166 $-21,381,677
Net Income Including Noncontrolling Interests $-13,451,931 - $-15,492,166 $-21,381,677
Net Income Continuous Operations $-13,451,931 - $-15,492,166 $-21,381,677
Pretax Income $-13,591,104 - $-15,579,486 $-21,520,851
Special Income Charges $-6,640,586 $0 - $-654,107
Interest Income Non Operating $665,571 - $220,097 $323,158
Operating Income $-9,009,576 - $-17,797,161 $-21,560,234
Net Income Discontinuous Operations - - - -
Depreciation Amortization Depletion Income Statement - - - -
Depreciation And Amortization In Income Statement - - - -
Amortization Of Intangibles Income Statement - - - -
Depreciation Income Statement - - - -
Per Share
Diluted EPS - $-0.23 $-18.62 $-0.16
Basic EPS - $-0.23 $-18.62 $-0.16
Other
Tax Effect Of Unusual Items $-52,471 $-44,827 $11,985 $-1,703
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-3,099,522 - $-19,131,748 $-20,613,267
Total Unusual Items $-5,247,099 - $1,997,578 $-283,775
Total Unusual Items Excluding Goodwill $-5,247,099 - $1,997,578 $-283,775
Reconciled Depreciation $662,955 - $662,991 $663,192
EBITDA (Bullshit earnings) $-8,346,621 - $-17,134,170 $-20,897,042
EBIT $-9,009,576 - $-17,797,161 $-21,560,234
Diluted NI Availto Com Stockholders $-13,451,931 - $-15,492,166 $-21,381,677
Tax Provision $-139,173 - $-87,320 $-139,174
Impairment Of Capital Assets $5,409,608 $0 - -
Restructuring And Mergern Acquisition $1,230,978 $0 - $654,107
Gain On Sale Of Security $1,393,487 - $1,997,578 $-283,775
Research And Development $3,545,421 - $9,417,785 $13,071,705
Selling General And Administration $7,439,224 - - $8,911,271
Other Gand A $7,439,224 - $8,474,591 $8,911,271
Diluted Average Shares - $1,622,924 $832,225 $122,394,618
Basic Average Shares - $1,622,924 $832,225 $122,394,618
Gain On Sale Of Ppe - - - $0
Rent And Landing Fees - - - $145,853
Amortization - - - -
Fetched: 2026-10-27
Balance Sheet (Annual)
Metric 2026-06-30 2024-06-30 2023-06-30 2022-06-30
Assets
Net Tangible Assets $16,959,740 $3,332,832 $7,186,124 $23,530,941
Total Assets $28,709,016 $27,649,093 $28,562,948 $44,927,475
Total Non Current Assets $7,640,282 $14,455,335 $15,236,336 $16,165,818
Goodwill And Other Intangible Assets $7,640,282 $14,157,540 $14,824,439 $15,619,941
Other Intangible Assets $4,142,060 $5,467,522 $6,130,253 $6,767,840
Current Assets $21,068,734 $13,193,758 $13,326,612 $28,761,657
Restricted Cash $0 - - $0
Prepaid Assets $389,772 $458,765 $797,478 $1,005,089
Receivables $813,431 $126,884 $426,087 $4,666,991
Other Receivables $810,778 $96,154 $416,072 $4,651,941
Taxes Receivable $2,653 $30,444 $9,758 $15,049
Accrued Interest Receivable $0 $286 $257 -
Cash Cash Equivalents And Short Term Investments $19,865,531 $12,608,109 $12,103,047 $23,089,577
Cash And Cash Equivalents $19,865,531 $12,608,109 $12,103,047 $23,089,577
Other Non Current Assets - $78,826 $78,897 $81,861
Cash Financial - - $18,250,255 $23,089,577
Non Current Prepaid Assets - - - -
Other Current Assets - - - -
Accounts Receivable - - - -
Gross Accounts Receivable - - - -
Debt
Total Debt $34,345 $272,738 $386,915 $477,150
Current Debt And Capital Lease Obligation $34,345 $155,110 $147,080 $110,093
Current Debt $34,345 $33,120 $33,150 -
Other Current Borrowings $34,345 $33,120 $33,150 -
Long Term Debt And Capital Lease Obligation - $117,628 $239,835 $367,057
Liabilities
Total Liabilities Net Minority Interest $4,108,994 $10,158,721 $6,552,385 $5,776,593
Total Non Current Liabilities Net Minority Interest $3,352,413 $6,329,648 $3,813,597 $3,468,217
Other Non Current Liabilities $1,025,301 $590,648 $2,471,049 $1,856,674
Derivative Product Liabilities $1,971,172 $4,657,832 $0 -
Non Current Deferred Liabilities $355,940 $963,540 $1,102,713 $1,237,291
Non Current Deferred Taxes Liabilities $355,940 $963,540 $1,102,713 $1,237,291
Current Liabilities $756,581 $3,829,073 $2,738,788 $2,308,376
Other Current Liabilities $53,165 $37,581 $39,405 -
Payables And Accrued Expenses $669,071 $3,636,382 $2,552,303 $1,916,708
Payables $385,584 $2,243,662 $1,439,291 $1,070,993
Accounts Payable $385,584 $2,243,662 $1,439,291 $1,070,993
Other Payable - - - -
Equity
Common Stock Equity $24,600,022 $17,490,372 $22,010,563 $39,150,882
Total Equity Gross Minority Interest $24,600,022 $17,490,372 $22,010,563 $39,150,882
Stockholders Equity $24,600,022 $17,490,372 $22,010,563 $39,150,882
Gains Losses Not Affecting Retained Earnings $-2,063,170 $-3,013,595 $-3,058,783 $8,615,100
Other Equity Adjustments $-2,063,170 $-3,013,595 $-3,058,783 -
Retained Earnings $-191,798,634 $-177,977,071 $-162,484,905 $-119,219,156
Other
Ordinary Shares Number $5,411,334 $198,711,663 $1,468,735,424 $1,353,350,744
Share Issued $5,411,334 $198,711,663 $1,468,735,424 $1,353,350,744
Tangible Book Value $16,959,740 $3,332,832 $7,186,124 $23,530,941
Invested Capital $24,634,367 $17,523,492 $22,043,713 $39,150,882
Working Capital $20,312,153 $9,364,685 $10,587,824 $26,453,281
Capital Lease Obligations $0 $239,618 $353,765 $477,150
Total Capitalization $24,600,022 $17,490,372 $22,010,563 $39,150,882
Additional Paid In Capital $218,461,772 $198,481,027 $187,554,251 -
Capital Stock $54 $11 $0 $149,754,939
Common Stock $54 $11 $0 $149,754,939
Current Capital Lease Obligation $0 $121,990 $113,930 $110,093
Current Accrued Expenses $283,487 $1,392,720 $1,113,012 $845,715
Goodwill $3,498,222 $8,690,018 $8,694,186 $8,852,101
Net PPE $0 $218,969 $333,000 $464,015
Gross PPE $0 $218,969 $378,237 $637,372
Long Term Capital Lease Obligation - $117,628 $239,835 $367,057
Accumulated Depreciation - $-45,722 $-45,237 $-173,357
Other Properties - $218,969 $330,478 -
Machinery Furniture Equipment - $47,716 $47,759 $49,554
Employee Benefits - - $22,398 $7,196
Pensionand Other Post Retirement Benefit Plans Current - - $457,017 $281,575
Leases - - $854,500 $587,819
Properties - - $0 $0
Foreign Currency Translation Adjustments - - - -
Non Current Pension And Other Postretirement Benefit Plans - - - -
Investments And Advances - - - -
Other Investments - - - -
Other Short Term Investments - - - -
Fetched: 2026-10-27
Cash Flow Statement (Annual)
Metric 2026-06-30 2025-06-30 2024-06-30 2023-06-30
Free Cash Flow
Free Cash Flow $-12,353,074 - $-14,680,777 $-14,637,720
Operating Activities
Operating Cash Flow $-12,353,074 - $-14,680,777 $-14,637,720
Cash Flow From Continuing Operating Activities $-12,353,074 - $-14,680,777 $-14,637,719
Operating Gains Losses $-1,127,008 - $-366,333 $-556,782
Cash Flowsfromusedin Operating Activities Direct - - - -
Classesof Cash Receiptsfrom Operating Activities - - - -
Investing Activities
Investing Cash Flow - - - $317,415
Cash Flow From Continuing Investing Activities - - - $317,415
Capital Expenditure - - - -
Financing Activities
Issuance Of Capital Stock $17,915,883 - $10,111,979 $3,858,451
Financing Cash Flow $17,915,883 - $15,108,794 $3,858,451
Cash Flow From Continuing Financing Activities $17,915,883 - $15,108,794 $3,858,451
Net Common Stock Issuance $17,915,883 - $10,111,979 $3,858,451
Common Stock Issuance $17,915,883 - $10,111,979 $3,858,451
Net Other Financing Charges - - - $-1,126,827
Repurchase Of Capital Stock - - - -
Other
Interest Paid Supplemental Data $3,857 - - -
End Cash Position $19,865,531 - $12,686,935 $12,181,944
Beginning Cash Position $14,288,690 - $12,181,944 $23,205,035
Effect Of Exchange Rate Changes $14,032 - $76,974 $-243,822
Changes In Cash $5,562,809 - $428,017 $-10,779,269
Change In Working Capital $-4,054,414 $-496,826 $1,454,857 $4,584,489
Change In Other Working Capital $-139,173 $-601,507 $-139,173 $-139,173
Change In Other Current Liabilities $-116,314 - $-126,111 $-99,767
Change In Payables And Accrued Expense $-3,347,865 - $1,082,225 $512,255
Change In Accrued Expense $-2,579,080 - $277,854 $138,079
Change In Payable $-768,785 - $804,371 $374,176
Change In Account Payable $-768,785 - $804,371 $374,176
Change In Prepaid Assets $350,421 - $338,713 $173,975
Change In Receivables $-801,483 - $299,203 $4,137,199
Changes In Account Receivables $-801,483 - $299,203 $4,137,199
Other Non Cash Items $-96,276 $831,017 $-1,754,934 $707,749
Stock Based Compensation $351,600 - $814,808 $1,345,309
Asset Impairment Charge $5,362,000 $0 - -
Depreciation Amortization Depletion $662,955 - $662,991 $663,192
Depreciation And Amortization $662,955 - $662,991 $663,192
Gain Loss On Investment Securities $-1,730,321 - $-338,983 -
Net Foreign Currency Exchange Gain Loss $603,313 - $-27,350 $-556,782
Net Income From Continuing Operations $-13,451,931 - $-15,492,166 $-21,381,677
Proceeds From Stock Option Exercised - - $4,996,815 $0
Repayment Of Debt - - - $-105,936
Net Issuance Payments Of Debt - - - $-105,936
Net Long Term Debt Issuance - - - $-105,936
Long Term Debt Payments - - - $-105,936
Interest Received Cfi - - - $317,415
Net Investment Purchase And Sale - - - $0
Sale Of Investment - - - $0
Purchase Of Investment - - - $0
Net PPE Purchase And Sale - - - $0
Sale Of PPE - - - $0
Purchase Of PPE - - - $0
Change In Other Current Assets - - - $170,945
Net Business Purchase And Sale - - - -
Purchase Of Business - - - -
Change In Inventory - - - -
Gain Loss On Sale Of PPE - - - -
Common Stock Payments - - - -
Interest Paid Direct - - - -
Classesof Cash Payments - - - -
Paymentsto Suppliersfor Goodsand Services - - - -
Receiptsfrom Government Grants - - - -
Receiptsfrom Customers - - - -
Fetched: 2026-10-27